ESPR
Esperion Therapeutics Inc
3.20$
+0.0%
vs. previous close
Closing price · As of: Jul 15, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 1999 | 2000 | 2001 | 2002 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 100.0% | – | – | – | – | 100.0% | – | – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | 39,300.0% | – | – | – | – | 0.0% | – | – | – | – | 93.0% | 118.4% | 1.1% | 18.1% | 35.7% | 37.2% | 20.6% | 32.1% | |
| – | -39,200.0% | – | – | – | – | 100.0% | – | – | – | – | 100.0% | 100.0% | 98.9% | 81.9% | 64.3% | 62.8% | 79.4% | 67.9% | |
| – | 1,089,450.0% | – | – | – | – | 0.3% | – | – | – | – | 93.0% | 118.4% | 64.6% | 135.1% | 157.6% | 74.0% | 13.9% | 11.9% | |
| – | – | – | – | – | – | 0.1% | – | – | – | – | 17.9% | 44.4% | 79.2% | 218.3% | 129.6% | 109.1% | 41.4% | 41.1% | |
| – | 1,339,400.0% | – | – | – | – | 0.5% | – | – | – | – | 110.9% | 162.8% | 152.3% | 370.9% | 302.1% | 196.5% | 63.0% | 53.0% | |
| – | -1,378,600.0% | – | – | – | – | -0.5% | – | – | – | – | -110.9% | -62.8% | -53.3% | -289.0% | -237.8% | -133.7% | 16.4% | 15.0% | |
| – | 0.0% | – | – | – | – | 0.0% | – | – | – | – | 0.1% | 5.5% | 10.0% | 59.1% | 75.3% | 50.7% | 17.8% | 21.0% | |
| – | -1,568,550.0% | – | – | – | – | -0.5% | – | – | – | – | -109.4% | -65.5% | -63.1% | -343.0% | -309.6% | -179.9% | -15.6% | -5.2% | |
| – | 205,200.0% | – | – | – | – | 0.0% | – | – | – | – | 1.6% | 8.0% | 9.9% | 63.4% | 71.8% | 0.0% | -15.6% | 0.5% | |
| – | -1,378,800.0% | – | – | – | – | -0.5% | – | – | – | – | -109.4% | -65.5% | -63.1% | -343.0% | -309.6% | -179.9% | -15.6% | -5.6% | |
| – | -1,276,100.0% | – | – | – | – | -0.5% | – | – | – | – | -110.8% | -59.8% | -52.9% | -283.2% | -233.7% | -129.0% | 2.3% | 15.8% |
Data as of: July 15, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.